{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:09:11Z","timestamp":1787004551103,"version":"build-2736575974"},"reference-count":327,"publisher":"Portland Press Ltd.","issue":"16","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Eicosanoids comprise a group of oxidation products of arachidonic and 5,8,11,14,17-eicosapentaenoic acids formed by oxygenases and downstream enzymes. The two major pathways for eicosanoid formation are initiated by the actions of 5-lipoxygenase (5-LO), leading to leukotrienes (LTs) and 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE), and cyclooxygenase (COX), leading to prostaglandins (PGs) and thromboxane (TX). A third group (specialized pro-resolving mediators; SPMs), including lipoxin A4 (LXA4) and resolvins (Rvs), are formed by the combined actions of different oxygenases. The actions of the above eicosanoids are mediated by approximately 20 G protein-coupled receptors, resulting in a variety of both detrimental and beneficial effects on airway smooth muscle and inflammatory cells that are strongly implicated in asthma pathophysiology. Drugs targeting proinflammatory eicosanoid receptors, including CysLT1, the receptor for LTD4 (montelukast) and TP, the receptor for TXA2 (seratrodast) are currently in use, whereas antagonists of a number of other receptors, including DP2 (PGD2), BLT1 (LTB4), and OXE (5-oxo-ETE) are under investigation. Agonists targeting anti-inflammatory\/pro-resolving eicosanoid receptors such as EP2\/4 (PGE2), IP (PGI2), ALX\/FPR2 (LXA4), and Chemerin1 (RvE1\/2) are also being examined. This review summarizes the contributions of eicosanoid receptors to the pathophysiology of asthma and the potential therapeutic benefits of drugs that target these receptors. Because of the multifactorial nature of asthma and the diverse pathways affected by eicosanoid receptors, it will be important to identify subgroups of asthmatics that are likely to respond to any given therapy.<\/jats:p>","DOI":"10.1042\/cs20190657","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T03:54:12Z","timestamp":1629172452000},"page":"1945-1980","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Eicosanoid receptors as therapeutic targets for asthma"],"prefix":"10.1042","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8507-4038","authenticated-orcid":false,"given":"William\u00a0S.","family":"Powell","sequence":"first","affiliation":[{"name":"Meakins-Christie Laboratories, Centre for Translational Biology, Research Institute of the McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"2021113011231792900_B1","doi-asserted-by":"publisher","first-page":"W260","DOI":"10.1093\/nar\/gkz303","article-title":"NGPhylogeny.fr: new generation phylogenetic services for non-specialists","volume":"47","author":"Lemoine","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"2021113011231792900_B2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.bbalip.2014.10.008","article-title":"Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid","volume":"1851","author":"Powell","year":"2015","journal-title":"Biochim. Biophys. Acta."},{"key":"2021113011231792900_B3","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1194\/jlr.R087882","article-title":"The arachidonic acid monooxygenase: from biochemical curiosity to physiological\/pathophysiological significance","volume":"59","author":"Capdevila","year":"2018","journal-title":"J. Lipid Res."},{"key":"2021113011231792900_B4","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1172\/JCI97943","article-title":"Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators","volume":"128","author":"Serhan","year":"2018","journal-title":"J. Clin. Invest."},{"key":"2021113011231792900_B5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3181\/00379727-28-5265","article-title":"Biochemical studies on human semen. II. The action of semen on the human uterus","volume":"28","author":"Kurzrok","year":"1930","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"2021113011231792900_B6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0304-4165(64)90145-X","article-title":"The enzymatic formation of prostaglandin E2 from arachidonic acid prostaglandins and related factors 32","volume":"90","author":"Bergstr\u00f6m","year":"1964","journal-title":"Biochim. Biophys. Acta."},{"key":"2021113011231792900_B7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1476-5381.1964.tb01705.x","article-title":"The inhibitory actions of prostaglandins on respiratory smooth muscle","volume":"22","author":"Main","year":"1964","journal-title":"Br. J. Pharmacol. Chemother."},{"key":"2021113011231792900_B8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/223029a0","article-title":"Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs","volume":"223","author":"Piper","year":"1969","journal-title":"Nature"},{"key":"2021113011231792900_B9","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1073\/pnas.72.8.2994","article-title":"Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides","volume":"72","author":"Hamberg","year":"1975","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011231792900_B10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1113\/expphysiol.1940.sp000825","article-title":"The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis","volume":"30","author":"Kellaway","year":"1940","journal-title":"Q. J. Exp. Physiol. Cogn Med. Sci."},{"key":"2021113011231792900_B11","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.76.9.4275","article-title":"Leukotriene C: a slow-reacting substance from murine mastocytoma cells","volume":"76","author":"Murphy","year":"1979","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011231792900_B12","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1073\/pnas.76.7.3213","article-title":"Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids","volume":"76","author":"Borgeat","year":"1979","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011231792900_B13","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1021\/cr200246d","article-title":"Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease","volume":"111","author":"Haeggstr\u00f6m","year":"2011","journal-title":"Chem.Rev."},{"key":"2021113011231792900_B14","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1164\/ajrccm.161.supplement_1.ltta-6","article-title":"Structure, function, and regulation of leukotriene A4 hydrolase","volume":"161","author":"Haeggstr\u00f6m","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021113011231792900_B15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1124\/pr.58.3.8","article-title":"Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses","volume":"58","author":"Folco","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"2021113011231792900_B16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S0090-6980(02)00052-7","article-title":"Leukotriene C4 synthase: a pivotal enzyme in cellular biosynthesis of the cysteinyl leukotrienes","volume":"68\u201369","author":"Lam","year":"2002","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"2021113011231792900_B17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1165\/rcmb.2019-0385OC","article-title":"Cellular source of cysteinyl leukotrienes following chlorine exposure","volume":"63","author":"McGovern","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2021113011231792900_B18","doi-asserted-by":"publisher","first-page":"19233","DOI":"10.1016\/S0021-9258(18)41766-8","article-title":"Metabolism of 5(S)-hydroxy-6,8,11,14-eicosatetraenoic acid and other 5(S)-hydroxyeicosanoids by a specific dehydrogenase in human polymorphonuclear leukocytes","volume":"267","author":"Powell","year":"1992","journal-title":"J. Biol. Chem."},{"key":"2021113011231792900_B19","doi-asserted-by":"publisher","first-page":"25373","DOI":"10.1016\/S0021-9258(18)47259-6","article-title":"Phorbol myristate acetate stimulates the formation of 5-oxo-6,8,11,14-eicosatetraenoic acid by human neutrophils by activating NADPH oxidase","volume":"269","author":"Powell","year":"1994","journal-title":"J. Biol. Chem."},{"key":"2021113011231792900_B20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.freeradbiomed.2009.04.016","article-title":"Oxidative stress-induced changes in pyridine nucleotides and chemoattractant 5-lipoxygenase products in aging neutrophils","volume":"47","author":"Graham","year":"2009","journal-title":"Free Radic.Biol.Med."},{"key":"2021113011231792900_B21","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.plipres.2013.09.001","article-title":"The eosinophil chemoattractant 5-oxo-ETE and the OXE receptor","volume":"52","author":"Powell","year":"2013","journal-title":"Prog. Lipid Res."},{"key":"2021113011231792900_B22","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/bph.14336","article-title":"Identification and structure elucidation of the pro-resolving mediators provides novel leads for resolution pharmacology","volume":"176","author":"Dalli","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"2021113011231792900_B23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/0006-291X(84)91486-4","article-title":"Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes","volume":"118","author":"Serhan","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113011231792900_B24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.plefa.2005.05.002","article-title":"Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution","volume":"73","author":"Serhan","year":"2005","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"2021113011231792900_B25","doi-asserted-by":"publisher","first-page":"C870","DOI":"10.1152\/ajpcell.1999.277.5.C870","article-title":"Hepatocytes are a rich source of novel aspirin-triggered 15-epi-lipoxin A(4)","volume":"277","author":"Titos","year":"1999","journal-title":"Am. J. Physiol."},{"key":"2021113011231792900_B26","doi-asserted-by":"publisher","first-page":"5922","DOI":"10.1021\/cr100396c","article-title":"Resolvins and protectins in inflammation resolution","volume":"111","author":"Serhan","year":"2011","journal-title":"Chem.Rev."},{"key":"2021113011231792900_B27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bbrc.2005.07.181","article-title":"The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids","volume":"338","author":"Arita","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113011231792900_B28","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1096\/fj.201701493R","article-title":"New maresin conjugates in tissue regeneration pathway counters leukotriene D4-stimulated vascular responses","volume":"32","author":"Chiang","year":"2018","journal-title":"FASEB J."},{"key":"2021113011231792900_B29","doi-asserted-by":"publisher","first-page":"5821","DOI":"10.1021\/cr2002992","article-title":"Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis","volume":"111","author":"Smith","year":"2011","journal-title":"Chem. Rev."},{"key":"2021113011231792900_B30","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/FJC.0b013e318157f72d","article-title":"COX-2 inhibitors and cardiovascular risk","volume":"50","author":"Funk","year":"2007","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2021113011231792900_B31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0952-3278(03)00077-2","article-title":"Hematopoietic prostaglandin D synthase","volume":"69","author":"Kanaoka","year":"2003","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"2021113011231792900_B32","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.biochi.2010.02.007","article-title":"Prostaglandin E synthases: Understanding their pathophysiological roles through mouse genetic models","volume":"92","author":"Hara","year":"2010","journal-title":"Biochimie"},{"key":"2021113011231792900_B33","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1073\/pnas.71.9.3400","article-title":"Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets","volume":"71","author":"Hamberg","year":"1974","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011231792900_B34","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/263663a0","article-title":"An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation","volume":"263","author":"Moncada","year":"1976","journal-title":"Nature"},{"key":"2021113011231792900_B35","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1124\/pr.110.003517","article-title":"International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress","volume":"63","author":"Woodward","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"2021113011231792900_B36","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1182\/blood.V98.6.1942","article-title":"Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor","volume":"98","author":"Monneret","year":"2001","journal-title":"Blood"},{"key":"2021113011231792900_B37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1084\/jem.193.2.255","article-title":"Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2","volume":"193","author":"Hirai","year":"2001","journal-title":"J. Exp. Med."},{"key":"2021113011231792900_B38","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1084\/jem.192.3.421","article-title":"A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders","volume":"192","author":"Yokomizo","year":"2000","journal-title":"J. Exp. Med."},{"key":"2021113011231792900_B39","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1084\/jem.20072329","article-title":"12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2","volume":"205","author":"Okuno","year":"2008","journal-title":"J. Exp. Med."},{"key":"2021113011231792900_B40","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1172\/JCI97946","article-title":"Leukotriene receptors as potential therapeutic targets","volume":"128","author":"Yokomizo","year":"2018","journal-title":"J. Clin. Invest."},{"key":"2021113011231792900_B41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/bs.ai.2019.04.002","article-title":"Roles of cysteinyl leukotrienes and their receptors in immune cell-related functions","volume":"142","author":"Kanaoka","year":"2019","journal-title":"Adv. Immunol."},{"key":"2021113011231792900_B42","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1002\/cmdc.201600453","article-title":"The G protein-coupled receptor GPR17: overview and update","volume":"11","author":"Marucci","year":"2016","journal-title":"Chem. Med. Chem."},{"key":"2021113011231792900_B43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1124\/jpet.113.207647","article-title":"Is GPR17 a P2Y\/leukotriene receptor? Examination of uracil nucleotides, nucleotide sugars, and cysteinyl leukotrienes as agonists of GPR17","volume":"347","author":"Qi","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021113011231792900_B44","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1124\/mol.116.107904","article-title":"The orphan receptor GPR17 is unresponsive to uracil nucleotides and cysteinyl leukotrienes","volume":"91","author":"Simon","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"2021113011231792900_B45","doi-asserted-by":"publisher","first-page":"11685","DOI":"10.1073\/pnas.0905364106","article-title":"GPR17 is a negative regulator of the cysteinyl leukotriene 1 receptor response to leukotriene D4","volume":"106","author":"Maekawa","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011231792900_B46","doi-asserted-by":"publisher","first-page":"113930","DOI":"10.1016\/j.bcp.2020.113930","article-title":"Targeting the OXE receptor as a potential novel therapy for asthma","volume":"179","author":"Powell","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"2021113011231792900_B47","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1073\/pnas.0907342107","article-title":"Resolvin D1 binds human phagocytes with evidence for proresolving receptors","volume":"107","author":"Krishnamoorthy","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011231792900_B48","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1124\/pr.116.013177","article-title":"International Union of Basic and Clinical Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) Nomenclature, Pharmacology, and Function","volume":"70","author":"Kennedy","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"2021113011231792900_B49","doi-asserted-by":"publisher","first-page":"L1053","DOI":"10.1152\/ajplung.1997.272.6.L1053","article-title":"5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice","volume":"272","author":"Irvin","year":"1997","journal-title":"Am. J. Physiol."},{"key":"2021113011231792900_B50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3389\/fmed.2017.00158","article-title":"Asthma endotypes and an overview of targeted therapy for asthma","volume":"4","author":"Svenningsen","year":"2017","journal-title":"Front. Med."},{"key":"2021113011231792900_B51","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.7326\/0003-4819-119-11-199312010-00001","article-title":"The effect of inhibition of 5-lipoxygenase by zileuton in mild- to-moderate asthma","volume":"119","author":"Israel","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"2021113011231792900_B52","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/thx.52.4.348","article-title":"Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005","volume":"52","author":"Hamilton","year":"1997","journal-title":"Thorax"},{"key":"2021113011231792900_B53","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2165\/00002018-200326070-00004","article-title":"Benefit-risk assessment of antileukotrienes in the management of asthma","volume":"26","author":"Garcia-Marcos","year":"2003","journal-title":"Drug Saf."},{"key":"2021113011231792900_B54","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1172\/JCI6890","article-title":"Allergic lung responses are increased in prostaglandin H synthase-deficient mice","volume":"104","author":"Gavett","year":"1999","journal-title":"J. Clin. Invest."},{"key":"2021113011231792900_B55","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11882-020-00905-9","article-title":"NSAID-ERD syndrome: the new hope from prevention, early diagnosis, and new therapeutic targets","volume":"20","author":"Laidlaw","year":"2020","journal-title":"Curr. Allergy Asthma Rep."},{"key":"2021113011231792900_B56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.it.2003.11.001","article-title":"The lung as a privileged site for the beneficial actions of PGE2","volume":"25","author":"Vancheri","year":"2004","journal-title":"Trends Immunol."},{"key":"2021113011231792900_B57","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/0006-291X(74)90246-0","article-title":"Prostaglandin endoperoxides. VII. Novel transformations of arachidonic acid in guinea pig lung","volume":"61","author":"Hamberg","year":"1974","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113011231792900_B58","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1476-5381.1982.tb09295.x","article-title":"Stimulation of arachidonic acid metabolism and generation of thromboxane A2 by leukotrienes B4, C4 and D4 in guinea-pig lung in vitro","volume":"77","author":"Piper","year":"1982","journal-title":"Br. J. Pharmacol."},{"key":"2021113011231792900_B59","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0262-1746(82)80008-5","article-title":"Evidence for a mediator role of thromboxane A2 in the myotropic action of leukotriene B4 (LTB4) on the guinea-pig lung","volume":"8","author":"Sirois","year":"1982","journal-title":"Prostaglandins Leukot. Med."},{"key":"2021113011231792900_B60","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/jlb.50.2.140","article-title":"Biochemical and functional differences between eosinophils from animal species and man","volume":"50","author":"Sun","year":"1991","journal-title":"J. Leukoc. Biol."},{"key":"2021113011231792900_B61","doi-asserted-by":"publisher","first-page":"12482","DOI":"10.1016\/S0021-9258(18)42302-2","article-title":"Identification of 5-oxo-15-hydroxy-6,8,11,13-eicosatetraenoic acid as a novel and potent human eosinophil chemotactic eicosanoid","volume":"267","author":"Schwenk","year":"1992","journal-title":"J. Biol. Chem."},{"key":"2021113011231792900_B62","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.4049\/jimmunol.154.8.4123","article-title":"5-Oxo-6,8,11,14-eicosatetraenoic acid is a potent stimulator of human eosinophil migration","volume":"154","author":"Powell","year":"1995","journal-title":"J. Immunol."},{"key":"2021113011231792900_B63","doi-asserted-by":"publisher","first-page":"L32","DOI":"10.1152\/ajplung.00390.2002","article-title":"Allergen-induced airway disease is mouse strain dependent","volume":"285","author":"Whitehead","year":"2003","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2021113011231792900_B64","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1128\/IAI.01323-09","article-title":"Intrapulmonary administration of leukotriene B4 enhances pulmonary host defense against pneumococcal pneumonia","volume":"78","author":"Mancuso","year":"2010","journal-title":"Infect. Immun."},{"key":"2021113011231792900_B65","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1056\/NEJMra071371","article-title":"Leukotrienes","volume":"357","author":"Peters-Golden","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"2021113011231792900_B66","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/288484a0","article-title":"Leukotrienes are potent constrictors of human bronchi","volume":"288","author":"Dahl\u00e9n","year":"1980","journal-title":"Nature"},{"key":"2021113011231792900_B67","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1073\/pnas.78.6.3887","article-title":"Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response","volume":"78","author":"Dahl\u00e9n","year":"1981","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011231792900_B68","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0065-2776(08)60416-2","article-title":"Slow reacting substance of anaphylaxis","volume":"10","author":"Orange","year":"1969","journal-title":"Adv. Immunol."},{"key":"2021113011231792900_B69","first-page":"449","article-title":"Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro","volume":"126","author":"Marom","year":"1982","journal-title":"Am. Rev. Respir. Dis."},{"key":"2021113011231792900_B70","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2174\/138955708784567395","article-title":"Leukotrienes, antileukotrienes and asthma","volume":"8","author":"Montuschi","year":"2008","journal-title":"Mini Rev. Med. Chem."},{"key":"2021113011231792900_B71","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1378\/chest.114.4.1028","article-title":"Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma","volume":"114","author":"Obase","year":"1998","journal-title":"Chest"},{"key":"2021113011231792900_B72","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1164\/rccm.200206-509OC","article-title":"Effects of montelukast and budesonide on airway responses and airway inflammation in asthma","volume":"166","author":"Leigh","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021113011231792900_B73","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1056\/NEJM199807163390302","article-title":"Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction","volume":"339","author":"Leff","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"2021113011231792900_B74","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1164\/ajrccm.165.1.2010080","article-title":"Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial","volume":"165","author":"Dahlen","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021113011231792900_B75","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1124\/mol.56.3.657","article-title":"Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor","volume":"56","author":"Sarau","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"2021113011231792900_B76","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/21658","article-title":"Characterization of the human cysteinyl leukotriene CysLT1 receptor","volume":"399","author":"Lynch","year":"1999","journal-title":"Nature"},{"key":"2021113011231792900_B77","doi-asserted-by":"publisher","first-page":"eaax2518","DOI":"10.1126\/sciadv.aax2518","article-title":"Structure-based mechanism of cysteinyl leukotriene receptor inhibition by antiasthmatic drugs","volume":"5","author":"Luginina","year":"2019","journal-title":"Sci. Adv."},{"key":"2021113011231792900_B78","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1165\/rcmb.2005-0124OC","article-title":"Localization and upregulation of cysteinyl leukotriene-1 receptor in asthmatic bronchial mucosa","volume":"33","author":"Zhu","year":"2005","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2021113011231792900_B79","first-page":"1406","article-title":"Pharmacological profile of leukotrienes E4, N-acetyl E4 and of four of their novel omega- and beta-oxidative metabolites in airways of guinea-pig and man in vitro","volume":"98","author":"Samhoun","year":"1989","journal-title":"Br. J. Pharmacol."},{"key":"2021113011231792900_B80","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1046\/j.1365-2222.2003.01696.x","article-title":"Effects of cysteinyl leukotrienes in small human bronchus and antagonist activity of montelukast and its metabolites","volume":"33","author":"Mechiche","year":"2003","journal-title":"Clin. Exp. Allergy"},{"key":"2021113011231792900_B81","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1164\/ajrccm\/148.2.413","article-title":"Role of leukotriene D4 in allergen-induced increases in airway smooth muscle in the rat","volume":"148","author":"Wang","year":"1993","journal-title":"Am. Rev. Respir. Dis."},{"key":"2021113011231792900_B82","doi-asserted-by":"publisher","first-page":"L808","DOI":"10.1152\/ajplung.00438.2009","article-title":"LTD(4) induces HB-EGF-dependent CXCL8 release through EGFR activation in human bronchial epithelial cells","volume":"299","author":"McGovern","year":"2010","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2021113011231792900_B83","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1164\/rccm.200501-088OC","article-title":"Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade","volume":"173","author":"Henderson","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021113011231792900_B84","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1164\/ajrccm.155.4.9105062","article-title":"The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma","volume":"155","author":"Diamant","year":"1997","journal-title":"Am. J. Respir. Crit Care Med."},{"key":"2021113011231792900_B85","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1164\/ajrccm.159.5.9810095","article-title":"Effect of inhaled leukotriene D4 on airway eosinophilia and airway hyperresponsiveness in asthmatic subjects","volume":"159","author":"Mulder","year":"1999","journal-title":"Am. J. Respir. Crit Care Med."},{"key":"2021113011231792900_B86","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1164\/ajrccm.164.8.2102033","article-title":"Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma","volume":"164","author":"Gauvreau","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021113011231792900_B87","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jaci.2018.02.024","article-title":"Leukotriene E4 induces airflow obstruction and mast cell activation through the cysteinyl leukotriene type 1 receptor","volume":"142","author":"Lazarinis","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B88","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jaci.2009.05.046","article-title":"The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications","volume":"124","author":"Austen","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B89","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jaci.2006.03.010","article-title":"Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism","volume":"118","author":"Langlois","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B90","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jaci.2012.01.057","article-title":"Human T(H)2 cells respond to cysteinyl leukotrienes through selective expression of cysteinyl leukotriene receptor 1","volume":"129","author":"Parmentier","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B91","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jaci.2014.09.006","article-title":"Prostaglandin D2 and leukotriene E4 synergize to stimulate diverse TH2 functions and TH2 cell\/neutrophil crosstalk","volume":"135","author":"Xue","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B92","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaci.2013.03.048","article-title":"Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production","volume":"132","author":"Doherty","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B93","doi-asserted-by":"publisher","first-page":"1090.e1011","DOI":"10.1016\/j.jaci.2016.12.958","article-title":"Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines","volume":"140","author":"Salimi","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B94","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41385-018-0049-9","article-title":"Synergistic activation of pro-inflammatory type-2 CD8(+) T lymphocytes by lipid mediators in severe eosinophilic asthma","volume":"11","author":"Hilvering","year":"2018","journal-title":"Mucosal Immunol."},{"key":"2021113011231792900_B95","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.4049\/jimmunol.170.8.4290","article-title":"Up-regulation of cysteinyl leukotriene 1 receptor by IL-13 enables human lung fibroblasts to respond to leukotriene C4 and produce eotaxin","volume":"170","author":"Chibana","year":"2003","journal-title":"J. Immunol."},{"key":"2021113011231792900_B96","doi-asserted-by":"publisher","first-page":"e43544","DOI":"10.1371\/journal.pone.0043544","article-title":"Leukotriene D4 and interleukin-13 cooperate to increase the release of eotaxin-3 by airway epithelial cells","volume":"7","author":"Provost","year":"2012","journal-title":"PLoS ONE"},{"key":"2021113011231792900_B97","doi-asserted-by":"publisher","first-page":"22779","DOI":"10.1074\/jbc.M101436200","article-title":"Extranuclear lipid bodies, elicited by CCR3-mediated signaling pathways, are the sites of chemokine-enhanced leukotriene C4 production in eosinophils and basophils","volume":"276","author":"Bandeira-Melo","year":"2001","journal-title":"J. Biol. Chem."},{"key":"2021113011231792900_B98","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.4049\/jimmunol.167.5.2855","article-title":"IL-13 and IL-4 up-regulate cysteinyl leukotriene 1 receptor expression in human monocytes and macrophages","volume":"167","author":"Thivierge","year":"2001","journal-title":"J. Immunol."},{"key":"2021113011231792900_B99","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1067\/mai.2003.1451","article-title":"CysLT1 receptor upregulation by TGF-beta and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4","volume":"111","author":"Espinosa","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B100","doi-asserted-by":"publisher","first-page":"808.e802","DOI":"10.1016\/j.jaci.2019.10.037","article-title":"IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways","volume":"145","author":"Manson","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B101","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2019.09.028","article-title":"Cysteinyl maresins regulate the prophlogistic lung actions of cysteinyl leukotrienes","volume":"145","author":"Levy","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B102","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1164\/rccm.201301-0023PP","article-title":"Antileukotriene agents for the treatment of lung disease","volume":"188","author":"Scott","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021113011231792900_B103","doi-asserted-by":"publisher","first-page":"487","DOI":"10.7326\/0003-4819-130-6-199903160-00005","article-title":"Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast\/Beclomethasone Study Group","volume":"130","author":"Malmstr\u00f6m","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"2021113011231792900_B104","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.iac.2018.06.011","article-title":"Urinary leukotriene E4 as a biomarker of exposure, susceptibility, and risk in asthma: an update","volume":"38","author":"Hoffman","year":"2018","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"2021113011231792900_B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2017.06.128","article-title":"Sex-biased eicosanoid biology: Impact for sex differences in inflammation and consequences for pharmacotherapy","volume":"145","author":"Pace","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"2021113011231792900_B106","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fphar.2016.00299","article-title":"Cysteinyl leukotrienes pathway genes, atopic asthma and drug response: from population isolates to large genome-wide association studies","volume":"7","author":"Thompson","year":"2016","journal-title":"Front. Pharmacol."},{"key":"2021113011231792900_B107","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1182\/blood-2007-07-100453","article-title":"CysLT(2) receptors interact with CysLT(1) receptors and down-modulate cysteinyl leukotriene-dependent mitogenic responses of mast cells","volume":"110","author":"Jiang","year":"2007","journal-title":"Blood"},{"key":"2021113011231792900_B108","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/0929-7855(95)00027-N","article-title":"Leukotriene receptors","volume":"12","author":"Metters","year":"1995","journal-title":"J. Lipid Mediat. Cell Signal."},{"key":"2021113011231792900_B109","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1006\/bbrc.2000.3140","article-title":"The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor","volume":"274","author":"Takasaki","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113011231792900_B110","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1124\/mol.58.6.1601","article-title":"Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist","volume":"58","author":"Nothacker","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"2021113011231792900_B111","doi-asserted-by":"publisher","first-page":"30531","DOI":"10.1074\/jbc.M003490200","article-title":"Characterization of the human cysteinyl leukotriene 2 receptor","volume":"275","author":"Heise","year":"2000","journal-title":"J. Biol. Chem."},{"key":"2021113011231792900_B112","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.1038\/s41467-019-13348-2","article-title":"Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors","volume":"10","author":"Gusach","year":"2019","journal-title":"Nat. Commun."},{"key":"2021113011231792900_B113","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.prostaglandins.2015.03.007","article-title":"Autocrine activity of cysteinyl leukotrienes in human vascular endothelial cells: signaling through the CysLT(2) receptor","volume":"120","author":"Capra","year":"2015","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"2021113011231792900_B114","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1476-5381.2010.00730.x","article-title":"Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor","volume":"160","author":"Wunder","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"2021113011231792900_B115","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1124\/jpet.111.186031","article-title":"A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia\/reperfusion injury and vascular permeability in mice","volume":"339","author":"Ni","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021113011231792900_B116","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3109\/09537101003615394","article-title":"Functional expression of cysteinyl leukotriene receptors on human platelets","volume":"21","author":"Hasegawa","year":"2010","journal-title":"Platelets"},{"key":"2021113011231792900_B117","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaci.2005.12.1342","article-title":"Toll-like receptor agonists differentially regulate cysteinyl-leukotriene receptor 1 expression and function in human dendritic cells","volume":"117","author":"Thivierge","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B118","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13223-019-0395-5","article-title":"Expression of COX-1, COX-2, 5-LOX and CysLT 2 in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease","volume":"15","author":"Vorsprach","year":"2019","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"2021113011231792900_B119","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1046\/j.1365-2222.2003.01786.x","article-title":"Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis","volume":"33","author":"Figueroa","year":"2003","journal-title":"Clin. Exp. Allergy"},{"key":"2021113011231792900_B120","doi-asserted-by":"publisher","first-page":"11589","DOI":"10.1073\/pnas.2034927100","article-title":"Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: functional distinction from CysLT1R","volume":"100","author":"Mellor","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011231792900_B121","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1073\/pnas.1817325115","article-title":"Cysteinyl leukotriene 2 receptor promotes endothelial permeability, tumor angiogenesis, and metastasis","volume":"116","author":"Duah","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011231792900_B122","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.neuroscience.2019.10.048","article-title":"Cysteinyl leukotriene receptor 2 is involved in inflammation and neuronal damage by mediating microglia M1\/M2 polarization through NF-kappaB pathway","volume":"422","author":"Zhao","year":"2019","journal-title":"Neuroscience"},{"key":"2021113011231792900_B123","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/00008571-200310000-00008","article-title":"A cysteinyl leukotriene 2 receptor variant is associated with atopy in the population of Tristan da Cunha","volume":"13","author":"Thompson","year":"2003","journal-title":"Pharmacogenetics"},{"key":"2021113011231792900_B124","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/00008571-200409000-00007","article-title":"A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma","volume":"14","author":"Pillai","year":"2004","journal-title":"Pharmacogenetics"},{"key":"2021113011231792900_B125","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1124\/jpet.110.172411","article-title":"Differential signaling defects associated with the M201V polymorphism in the cysteinyl leukotriene type 2 receptor","volume":"336","author":"Brochu-Bourque","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021113011231792900_B126","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.plefa.2018.03.007","article-title":"Increased expression of CysLT2 receptors in the lung of asthmatic mice and role in allergic responses","volume":"131","author":"Matsuda","year":"2018","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"2021113011231792900_B127","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.4049\/jimmunol.1500905","article-title":"Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway","volume":"195","author":"Liu","year":"2015","journal-title":"J. Immunol."},{"key":"2021113011231792900_B128","doi-asserted-by":"publisher","first-page":"915","DOI":"10.4049\/jimmunol.1700603","article-title":"Type 2 cysteinyl leukotriene receptors drive IL-33-dependent type 2 immunopathology and aspirin sensitivity","volume":"200","author":"Liu","year":"2018","journal-title":"J. Immunol."},{"key":"2021113011231792900_B129","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.4049\/jimmunol.1201865","article-title":"Cysteinyl leukotriene 2 receptor on dendritic cells negatively regulates ligand-dependent allergic pulmonary inflammation","volume":"189","author":"Barrett","year":"2012","journal-title":"J. Immunol."},{"key":"2021113011231792900_B130","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1111\/all.12987","article-title":"A dual CysLT1\/2 antagonist attenuates allergen-induced airway responses in subjects with mild allergic asthma","volume":"71","author":"Gauvreau","year":"2016","journal-title":"Allergy"},{"key":"2021113011231792900_B131","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1476-5381.1991.tb12518.x","article-title":"The mechanism of LTE4-induced histamine hyperresponsiveness in guinea-pig tracheal and human bronchial smooth muscle, in vitro","volume":"104","author":"Jacques","year":"1991","journal-title":"Br. J. Pharmacol."},{"key":"2021113011231792900_B132","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.1073\/pnas.81.15.4922","article-title":"Leukotriene E4-induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors","volume":"81","author":"Lee","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011231792900_B133","doi-asserted-by":"publisher","first-page":"16695","DOI":"10.1073\/pnas.0808993105","article-title":"Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors","volume":"105","author":"Maekawa","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011231792900_B134","doi-asserted-by":"publisher","first-page":"10967","DOI":"10.1074\/jbc.C113.453704","article-title":"Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand","volume":"288","author":"Kanaoka","year":"2013","journal-title":"J. Biol. Chem."},{"key":"2021113011231792900_B135","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/nature02488","article-title":"Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors","volume":"429","author":"He","year":"2004","journal-title":"Nature"},{"key":"2021113011231792900_B136","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00441-015-2318-1","article-title":"Expression and localization of GPR91 and GPR99 in murine organs","volume":"364","author":"Diehl","year":"2016","journal-title":"Cell Tissue Res."},{"key":"2021113011231792900_B137","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.1073\/pnas.1605957113","article-title":"Leukotriene E-4 elicits respiratory epithelial cell mucin release through the G-protein-coupled receptor, GPR99","volume":"113","author":"Bankova","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011231792900_B138","doi-asserted-by":"publisher","first-page":"eaat9453","DOI":"10.1126\/sciimmunol.aat9453","article-title":"The cysteinyl leukotriene 3 receptor regulates expansion of IL-25-producing airway brush cells leading to type 2 inflammation","volume":"3","author":"Bankova","year":"2018","journal-title":"Sci. Immunol."},{"key":"2021113011231792900_B139","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1084\/jem.20091240","article-title":"Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor","volume":"206","author":"Paruchuri","year":"2009","journal-title":"J. Exp. Med."},{"key":"2021113011231792900_B140","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.alit.2014.11.002","article-title":"Leukotriene E4 induces MUC5AC release from human airway epithelial NCI-H292 cells","volume":"64","author":"Shirasaki","year":"2015","journal-title":"Allergol. Int."},{"key":"2021113011231792900_B141","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/286264a0","article-title":"Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes","volume":"286","author":"Ford-Hutchinson","year":"1980","journal-title":"Nature"},{"key":"2021113011231792900_B142","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/42506","article-title":"A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis","volume":"387","author":"Yokomizo","year":"1997","journal-title":"Nature"},{"key":"2021113011231792900_B143","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nchembio.2547","article-title":"Na(+)-mimicking ligands stabilize the inactive state of leukotriene B4 receptor BLT1","volume":"14","author":"Hori","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"2021113011231792900_B144","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/intimm\/dxz044","article-title":"The leukotriene receptors as therapeutic targets of inflammatory diseases","volume":"31","author":"Sasaki","year":"2019","journal-title":"Int. Immunol."},{"key":"2021113011231792900_B145","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaci.2009.03.024","article-title":"Expression of functional leukotriene B4 receptors on human airway smooth muscle cells","volume":"124","author":"Watanabe","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B146","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1084\/jem.20042407","article-title":"Leukotriene B4, an activation product of mast cells, is a chemoattractant for their progenitors","volume":"201","author":"Weller","year":"2005","journal-title":"J. Exp. Med."},{"key":"2021113011231792900_B147","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0091-6749(89)90173-5","article-title":"Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases","volume":"84","author":"Wardlaw","year":"1989","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B148","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1172\/JCI114338","article-title":"Effects of leukotriene B4 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability","volume":"84","author":"Martin","year":"1989","journal-title":"J. Clin. Invest."},{"key":"2021113011231792900_B149","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/ni970","article-title":"Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment","volume":"4","author":"Tager","year":"2003","journal-title":"Nat. Immunol."},{"key":"2021113011231792900_B150","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/ni972","article-title":"Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues","volume":"4","author":"Goodarzi","year":"2003","journal-title":"Nat. Immunol."},{"key":"2021113011231792900_B151","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1164\/rccm.200502-205OC","article-title":"Requirement for leukotriene B4 receptor 1 in allergen-induced airway hyperresponsiveness","volume":"172","author":"Miyahara","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021113011231792900_B152","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.4049\/jimmunol.175.7.4217","article-title":"Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses","volume":"175","author":"Terawaki","year":"2005","journal-title":"J. Immunol."},{"key":"2021113011231792900_B153","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.smim.2017.08.005","article-title":"Importance of the leukotriene B4-BLT1 and LTB4-BLT2 pathways in asthma","volume":"33","author":"Gelfand","year":"2017","journal-title":"Semin. Immunol."},{"key":"2021113011231792900_B154","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1136\/thx.51.12.1178","article-title":"Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma","volume":"51","author":"Evans","year":"1996","journal-title":"Thorax"},{"key":"2021113011231792900_B155","article-title":"The effect of BIIL 284 BS (14-day treatment) on induced-sputum variables in patients with bronchial asthma (a double-blind, randomized, placebo-controlled, parallel study)","author":"Boehringer-Ingelheim","year":"2000","journal-title":"Clinical Study Synopsis for Public Disclosure"},{"key":"2021113011231792900_B156","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pupt.2014.06.003","article-title":"Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma","volume":"29","author":"Barchuk","year":"2014","journal-title":"Pulm. Pharmacol. Ther."},{"key":"2021113011231792900_B157","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.bbrc.2006.07.084","article-title":"Leukotriene B4 stimulates human monocyte-derived dendritic cell chemotaxis","volume":"348","author":"Shin","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113011231792900_B158","doi-asserted-by":"publisher","first-page":"6329","DOI":"10.4049\/jimmunol.1001213","article-title":"BLT2 Is upregulated in allergen-stimulated mast cells and mediates the synthesis of Th2 cytokines","volume":"185","author":"Cho","year":"2010","journal-title":"J. Immunol."},{"key":"2021113011231792900_B159","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1096\/fj.12-217000","article-title":"Leukotriene B4 receptor BLT2 negatively regulates allergic airway eosinophilia","volume":"27","author":"Matsunaga","year":"2013","journal-title":"FASEB J."},{"key":"2021113011231792900_B160","doi-asserted-by":"publisher","first-page":"6117","DOI":"10.1002\/jcp.26455","article-title":"Leukotriene B4 receptor 2 regulates the proliferation, migration, and barrier integrity of bronchial epithelial cells","volume":"233","author":"Liu","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"2021113011231792900_B161","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/cea.12990","article-title":"The effect of allergen-induced bronchoconstriction on concentration of 5-oxo-ETE in exhaled breath condensate of house dust mite-allergic patients","volume":"47","author":"Kowal","year":"2017","journal-title":"Clin. Exp. Allergy"},{"key":"2021113011231792900_B162","doi-asserted-by":"publisher","first-page":"31459","DOI":"10.1074\/jbc.M203194200","article-title":"Identification of a novel eicosanoid receptor coupled to Gi\/o","volume":"277","author":"Hosoi","year":"2002","journal-title":"J. Biol. Chem."},{"key":"2021113011231792900_B163","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2220\/biomedres.23.101","article-title":"Identification of a G protein-coupled receptor for 5-oxo-eicosatetraenoic acid","volume":"23","author":"Takeda","year":"2002","journal-title":"Biomed. Res."},{"key":"2021113011231792900_B164","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1124\/mol.63.3.471","article-title":"Expression and characterization of a 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid receptor highly expressed on human eosinophils and neutrophils","volume":"63","author":"Jones","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"2021113011231792900_B165","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jaci.2005.08.001","article-title":"5-oxo-6,8,11,14-eicosatetraenoic acid is a potent chemoattractant for human basophils","volume":"116","author":"Sturm","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B166","doi-asserted-by":"publisher","first-page":"32535","DOI":"10.1074\/jbc.273.49.32535","article-title":"Receptors for the 5-oxo class of eicosanoids in neutrophils","volume":"273","author":"O'Flaherty","year":"1998","journal-title":"J. Biol. Chem."},{"key":"2021113011231792900_B167","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1016\/S0021-9258(18)98347-X","article-title":"Stimulation of human neutrophils by 5-oxo-6,8,11,14- eicosatetraenoic acid by a mechanism independent of the leukotriene B4 receptor","volume":"268","author":"Powell","year":"1993","journal-title":"J. Biol. Chem."},{"key":"2021113011231792900_B168","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nchembio.962","article-title":"A biased ligand for OXE-R uncouples G\u03b1 and G\u03b2\u03b3 signaling within a heterotrimer","volume":"8","author":"Bl\u00e4ttermann","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"2021113011231792900_B169","doi-asserted-by":"publisher","DOI":"10.1038\/srep44418","article-title":"Antagonizing effects of membrane-acting androgens on the eicosanoid receptor OXER1 in prostate cancer","volume":"7","author":"Kalyvianaki","year":"2017","journal-title":"Sci. Rep."},{"key":"2021113011231792900_B170","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1189\/jlb.69.5.772","article-title":"Eotaxin promotes eosinophil transmigration via the activation of the plasminogen-plasmin system","volume":"69","author":"Ferland","year":"2001","journal-title":"J. Leukoc. Biol."},{"key":"2021113011231792900_B171","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S0091-6749(03)01888-8","article-title":"5-Oxo-6,8,11,14-eicosatetraenoic acid induces the infiltration of granulocytes into human skin","volume":"112","author":"Muro","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B172","doi-asserted-by":"crossref","first-page":"336","DOI":"10.4049\/jimmunol.157.1.336","article-title":"5-Oxo-eicosatetraenoate is a broadly active, eosinophil-selective stimulus for human granulocytes","volume":"157","author":"O'Flaherty","year":"1996","journal-title":"J. Immunol."},{"key":"2021113011231792900_B173","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1183\/09031936.03.00102002","article-title":"Endothelial cells modulate eosinophil surface markers and mediator release","volume":"21","author":"Dallaire","year":"2003","journal-title":"Eur. Respir. J."},{"key":"2021113011231792900_B174","doi-asserted-by":"publisher","first-page":"28159","DOI":"10.1074\/jbc.M401537200","article-title":"5-oxo-6,8,11,14-eicosatetraenoic acid stimulates the release of the eosinophil survival factor granulocyte\/macrophage colony-stimulating factor from monocytes","volume":"279","author":"Stamatiou","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2021113011231792900_B175","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/bph.14874","article-title":"Novel highly potent OXE receptor antagonists with prolonged plasma lifetimes that are converted to active metabolites in vivo in monkeys","volume":"177","author":"Ye","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"2021113011231792900_B176","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.bcp.2015.05.009","article-title":"Biosynthesis and actions of 5-oxoeicosatetraenoic acid (5-oxo-ETE) on feline granulocytes","volume":"96","author":"Cossette","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"2021113011231792900_B177","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/bph.14872","article-title":"Inhibition of allergen-induced dermal eosinophilia by an oxoeicosanoid receptor antagonist in non-human primates","volume":"177","author":"Miller","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"2021113011231792900_B178","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1398-9995.1994.tb02654.x","article-title":"Effects of Lipoxin A, on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine","volume":"49","author":"Soyombo","year":"1994","journal-title":"Allergy"},{"key":"2021113011231792900_B179","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1084\/jem.180.1.253","article-title":"Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor","volume":"180","author":"Fiore","year":"1994","journal-title":"J. Exp. Med."},{"key":"2021113011231792900_B180","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41467-020-15009-1","article-title":"Structural basis of ligand binding modes at the human formyl peptide receptor 2","volume":"11","author":"Chen","year":"2020","journal-title":"Nat. Commun."},{"key":"2021113011231792900_B181","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1111\/bph.12665","article-title":"Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7","volume":"171","author":"B\u00e4ck","year":"2014","journal-title":"Brit J. Pharmacol."},{"key":"2021113011231792900_B182","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1432-1033.1969.tb00784.x","article-title":"15-Hydroxy-prostanoate dehydrogenase. Prostaglandins as substrates and inhibitors","volume":"11","author":"Nakano","year":"1969","journal-title":"Eur. J. Biochem."},{"key":"2021113011231792900_B183","doi-asserted-by":"publisher","first-page":"14609","DOI":"10.1021\/bi00044a041","article-title":"Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils","volume":"34","author":"Serhan","year":"1995","journal-title":"Biochemistry"},{"key":"2021113011231792900_B184","doi-asserted-by":"publisher","first-page":"7193","DOI":"10.3390\/ijms14047193","article-title":"Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists","volume":"14","author":"Cattaneo","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"2021113011231792900_B185","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.1096\/fj.201903206R","article-title":"Dual modulation of formyl peptide receptor 2 by aspirin-triggered lipoxin contributes to its anti-inflammatory activity","volume":"34","author":"Ge","year":"2020","journal-title":"FASEB J."},{"key":"2021113011231792900_B186","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pharmthera.2018.01.004","article-title":"Towards targeting resolution pathways of airway inflammation in asthma","volume":"186","author":"Barnig","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"2021113011231792900_B187","doi-asserted-by":"publisher","first-page":"174ra26","DOI":"10.1126\/scitranslmed.3004812","article-title":"Lipoxin A(4) regulates natural killer cell and Type 2 innate lymphoid cell activation in asthma","volume":"5","author":"Barnig","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"2021113011231792900_B188","doi-asserted-by":"publisher","first-page":"106428","DOI":"10.1016\/j.prostaglandins.2020.106428","article-title":"Lipoxin A4 reduces house dust mite and TNFalpha-induced hyperreactivity in the mouse trachea","volume":"149","author":"Abma","year":"2020","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"2021113011231792900_B189","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/nm748","article-title":"Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4","volume":"8","author":"Levy","year":"2002","journal-title":"Nat. Med."},{"key":"2021113011231792900_B190","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.4049\/jimmunol.1101665","article-title":"Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses","volume":"189","author":"Rogerio","year":"2012","journal-title":"J. Immunol."},{"key":"2021113011231792900_B191","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.21037\/jtd.2018.03.02","article-title":"Lipoxin A4 regulates PM2.5-induced severe allergic asthma in mice via the Th1\/Th2 balance of group 2 innate lymphoid cells","volume":"10","author":"Lu","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"2021113011231792900_B192","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.4049\/jimmunol.0903022","article-title":"A critical role for the g protein-coupled receptor mFPR2 in airway inflammation and immune responses","volume":"184","author":"Chen","year":"2010","journal-title":"J. Immunol."},{"key":"2021113011231792900_B193","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1164\/ajrccm\/145.6.1281","article-title":"The effects of lipoxin A4 on airway responses in asthmatic subjects","volume":"145","author":"Christie","year":"1992","journal-title":"Am. Rev. Respir. Dis."},{"key":"2021113011231792900_B194","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.3892\/etm.2017.4787","article-title":"Pilot application of lipoxin A4 analog and lipoxin A4 receptor agonist in asthmatic children with acute episodes","volume":"14","author":"Kong","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"2021113011231792900_B195","doi-asserted-by":"publisher","first-page":"113167","DOI":"10.1016\/j.ejmech.2021.113167","article-title":"Recent advances in the design and development of formyl peptide receptor 2 (FPR2\/ALX) agonists as pro-resolving agents with diverse therapeutic potential","volume":"213","author":"Maciuszek","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"2021113011231792900_B196","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1084\/jem.20042031","article-title":"Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1","volume":"201","author":"Arita","year":"2005","journal-title":"J. Exp. Med."},{"key":"2021113011231792900_B197","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1084\/jem.20030382","article-title":"Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids","volume":"198","author":"Wittamer","year":"2003","journal-title":"J. Exp. Med."},{"key":"2021113011231792900_B198","doi-asserted-by":"publisher","first-page":"6489","DOI":"10.4049\/jimmunol.0901037","article-title":"Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model","volume":"183","author":"Luangsay","year":"2009","journal-title":"J. Immunol."},{"key":"2021113011231792900_B199","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1096\/fj.07-8473com","article-title":"Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution","volume":"21","author":"Campbell","year":"2007","journal-title":"FASEB J."},{"key":"2021113011231792900_B200","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.bbrc.2010.08.025","article-title":"Protective effect of resolvin E1 on the development of asthmatic airway inflammation","volume":"400","author":"Aoki","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113011231792900_B201","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/ni.1627","article-title":"Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation","volume":"9","author":"Haworth","year":"2008","journal-title":"Nat. Immunol."},{"key":"2021113011231792900_B202","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1042\/CS20130623","article-title":"Resolvin E1 promotes resolution of inflammation in a mouse model of an acute exacerbation of allergic asthma","volume":"126","author":"Flesher","year":"2014","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113011231792900_B203","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.4049\/jimmunol.178.6.3912","article-title":"Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation","volume":"178","author":"Arita","year":"2007","journal-title":"J. Immunol."},{"key":"2021113011231792900_B204","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/349617a0","article-title":"Cloning and expression of cDNA for a human thromboxane A2 receptor","volume":"349","author":"Hirata","year":"1991","journal-title":"Nature"},{"key":"2021113011231792900_B205","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41589-018-0170-9","article-title":"Structural basis for ligand recognition of the human thromboxane A2 receptor","volume":"15","author":"Fan","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"2021113011231792900_B206","doi-asserted-by":"publisher","first-page":"19256","DOI":"10.1016\/S0021-9258(17)32161-0","article-title":"Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor","volume":"269","author":"Raychowdhury","year":"1994","journal-title":"J. Biol. Chem."},{"key":"2021113011231792900_B207","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pharmthera.2008.01.001","article-title":"Thromboxane A2: physiology\/pathophysiology, cellular signal transduction and pharmacology","volume":"118","author":"Nakahata","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"2021113011231792900_B208","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1172\/JCI118518","article-title":"Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation","volume":"97","author":"Hirata","year":"1996","journal-title":"J. Clin. Invest."},{"key":"2021113011231792900_B209","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1476-5381.1989.tb11869.x","article-title":"Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors","volume":"96","author":"Coleman","year":"1989","journal-title":"Br. J. Pharmacol."},{"key":"2021113011231792900_B210","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1365-2125.1994.tb04249.x","article-title":"Effects of a thromboxane receptor antagonist on prostaglandin D2 and histamine induced bronchoconstriction in man","volume":"37","author":"al Jarad","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2021113011231792900_B211","doi-asserted-by":"publisher","first-page":"L526","DOI":"10.1152\/ajplung.00340.2005","article-title":"Thromboxane A2 induces airway constriction through an M3 muscarinic acetylcholine receptor-dependent mechanism","volume":"290","author":"Allen","year":"2006","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2021113011231792900_B212","doi-asserted-by":"publisher","first-page":"L140","DOI":"10.1152\/ajplung.00152.2011","article-title":"Allergic inflammation induces a persistent mechanistic switch in thromboxane-mediated airway constriction in the mouse","volume":"302","author":"Cyphert","year":"2012","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2021113011231792900_B213","doi-asserted-by":"publisher","first-page":"L555","DOI":"10.1152\/ajplung.1992.263.5.L555","article-title":"Role and mechanism of thromboxane-induced proliferation of cultured airway smooth muscle cells","volume":"263","author":"Noveral","year":"1992","journal-title":"Am. J. Physiol."},{"key":"2021113011231792900_B214","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1183\/09031936.98.11030624","article-title":"Effect of thromboxane A2 inhibitors on allergic pulmonary inflammation in mice","volume":"11","author":"Shi","year":"1998","journal-title":"Eur. Respir. J."},{"key":"2021113011231792900_B215","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1046\/j.1365-2249.1998.00614.x","article-title":"Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells","volume":"112","author":"Ishizuka","year":"1998","journal-title":"Clin. Exp. Immunol."},{"key":"2021113011231792900_B216","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejphar.2008.09.044","article-title":"TP receptor-mediated release of eosinophil chemotactic activity from human bronchial smooth muscle cells","volume":"600","author":"Suzuki","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"2021113011231792900_B217","doi-asserted-by":"publisher","first-page":"12692","DOI":"10.1073\/pnas.1207816109","article-title":"Prostaglandin E2 deficiency uncovers a dominant role for thromboxane A2 in house dust mite-induced allergic pulmonary inflammation","volume":"109","author":"Liu","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011231792900_B218","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1378\/chest.109.2.338","article-title":"BAY u3405, a thromboxane A2 antagonist, reduces bronchial hyperresponsiveness in asthmatics","volume":"109","author":"Aizawa","year":"1996","journal-title":"Chest"},{"key":"2021113011231792900_B219","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1124\/jpet.102.046748","article-title":"An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro","volume":"305","author":"Sugimoto","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021113011231792900_B220","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0952-3278(98)90061-8","article-title":"Effects of thromboxane A2 antagonist on airway hyperresponsiveness, exhaled nitric oxide, and induced sputum eosinophils in asthmatics","volume":"59","author":"Aizawa","year":"1998","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"2021113011231792900_B221","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0091-6749(99)70179-X","article-title":"Effect of AA-2414, a thromboxane A2 receptor antagonist, on airway inflammation in subjects with asthma","volume":"103","author":"Hoshino","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B222","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.alit.2020.08.001","article-title":"Japanese guidelines for adult asthma 2020","volume":"69","author":"Nakamura","year":"2020","journal-title":"Allergol. Int."},{"key":"2021113011231792900_B223","article-title":"Therapeutic control of aspirin-exacerbated respiratory disease","author":"Brigham and Women\u2019s Hospital","year":"2020","journal-title":"ClinicalTrials.org."},{"key":"2021113011231792900_B224","article-title":"A phase 2 multicenter, double-blind, randomized, placebo-controlled trial to evaluate oral ifetroban in subjects with symptomatic Aspirin Exacerbated Respiratory Disease (AERD)","author":"Cumberland Pharmaceuticals","year":"2020","journal-title":"ClinicalTrials.org."},{"key":"2021113011231792900_B225","doi-asserted-by":"publisher","first-page":"18910","DOI":"10.1074\/jbc.270.32.18910","article-title":"Molecular cloning and characterization of the human prostanoid DP receptor","volume":"270","author":"Boie","year":"1995","journal-title":"J. Biol. Chem."},{"key":"2021113011231792900_B226","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/sj.bjp.0702392","article-title":"Prostanoid receptors involved in the relaxation of human bronchial preparations","volume":"126","author":"Norel","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"2021113011231792900_B227","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/0090-6980(84)90033-9","article-title":"Effects of intravenous infusions of prostaglandin D2 in man","volume":"28","author":"Heavey","year":"1984","journal-title":"Prostaglandins"},{"key":"2021113011231792900_B228","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/NEJM198609253151304","article-title":"Release of prostaglandin D2 into human airways during acute antigen challenge","volume":"315","author":"Murray","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"2021113011231792900_B229","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1126\/science.287.5460.2013","article-title":"Prostaglandin D2 as a mediator of allergic asthma","volume":"287","author":"Matsuoka","year":"2000","journal-title":"Science"},{"key":"2021113011231792900_B230","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejphar.2015.08.003","article-title":"Effect of the potent and selective DP1 receptor antagonist, asapiprant (S-555739), in animal models of allergic rhinitis and allergic asthma","volume":"765","author":"Takahashi","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"2021113011231792900_B231","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1067\/mai.2001.119919","article-title":"Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP","volume":"108","author":"Gervais","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B232","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.4049\/jimmunol.179.7.4792","article-title":"The role of the prostaglandin D2 receptor, DP, in eosinophil trafficking","volume":"179","author":"Schratl","year":"2007","journal-title":"J. Immunol."},{"key":"2021113011231792900_B233","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1183\/09031936.00061614","article-title":"Prostaglandin D2 and the role of the DP1, DP2 and TP receptors in the control of airway reflex events","volume":"45","author":"Maher","year":"2015","journal-title":"Eur. Respir. J."},{"key":"2021113011231792900_B234","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1056\/NEJMoa031785","article-title":"Role of prostanoid DP receptor variants in susceptibility to asthma","volume":"351","author":"Oguma","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2021113011231792900_B235","doi-asserted-by":"publisher","first-page":"942e941","DOI":"10.1016\/j.jaci.2009.07.006","article-title":"Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis","volume":"124","author":"Philip","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B236","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1124\/jpet.104.074823","article-title":"Effects of prostaglandin D2 and 5-lipoxygenase products on the expression of CD203c and CD11b by basophils","volume":"312","author":"Monneret","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021113011231792900_B237","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.anai.2011.01.027","article-title":"The opposing role of two prostaglandin D2 receptors, DP and CRTH2, in human eosinophil migration","volume":"106","author":"Chiba","year":"2011","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"2021113011231792900_B238","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1124\/jpet.104.079079","article-title":"Effects of prostaglandin D2, 15-deoxy-\u039412,14-prostaglandin J2, and selective DP1 and DP2 receptor agonists on pulmonary infiltration of eosinophils in Brown Norway rats","volume":"313","author":"Almishri","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021113011231792900_B239","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.4049\/jimmunol.174.6.3703","article-title":"Activation of the prostaglandin D2 receptor DP2\/CRTH2 increases allergic inflammation in mouse","volume":"174","author":"Spik","year":"2005","journal-title":"J. Immunol."},{"key":"2021113011231792900_B240","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1084\/jem.20061196","article-title":"Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells","volume":"204","author":"Hammad","year":"2007","journal-title":"J. Exp. Med."},{"key":"2021113011231792900_B241","doi-asserted-by":"publisher","first-page":"8202","DOI":"10.1096\/fj.201802817R","article-title":"Epithelial cell-derived prostaglandin D2 inhibits chronic allergic lung inflammation in mice","volume":"33","author":"Maehara","year":"2019","journal-title":"FASEB J."},{"key":"2021113011231792900_B242","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/cea.13831","article-title":"Selective inhibition of prostaglandin D2 biosynthesis in human mast cells to overcome need for multiple receptor antagonists: Biochemical consequences","volume":"51","author":"Johnsson","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"2021113011231792900_B243","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jaci.2012.10.013","article-title":"Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients","volume":"131","author":"Busse","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B244","doi-asserted-by":"publisher","first-page":"48.e44","DOI":"10.1016\/j.molcel.2018.08.009","article-title":"Structures of the Human PGD2 Receptor CRTH2 reveal novel mechanisms for ligand recognition","volume":"72","author":"Wang","year":"2018","journal-title":"Mol. Cell"},{"key":"2021113011231792900_B245","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1124\/jpet.106.111062","article-title":"Agonist and antagonist effects of 15R-prostaglandin (PG) D2 and 11-methylene-PGD2 on human eosinophils and basophils","volume":"320","author":"Cossette","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021113011231792900_B246","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.4049\/jimmunol.168.7.3563","article-title":"15-Deoxy-\u039412,14-prostaglandins D2 and J2 are potent activators of human eosinophils","volume":"168","author":"Monneret","year":"2002","journal-title":"J. Immunol."},{"key":"2021113011231792900_B247","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/0092-8674(95)90193-0","article-title":"15-Deoxy-\u039412,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR-\u03b3","volume":"83","author":"Forman","year":"1995","journal-title":"Cell"},{"key":"2021113011231792900_B248","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1124\/jpet.102.042937","article-title":"15R-Methyl-prostaglandin D2 is a potent and selective CRTH2\/DP2 receptor agonist in human eosinophils","volume":"304","author":"Monneret","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021113011231792900_B249","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.4049\/jimmunol.162.3.1278","article-title":"Selective expression of a novel surface molecule by human Th2 cells in vivo","volume":"162","author":"Nagata","year":"1999","journal-title":"J. Immunol."},{"key":"2021113011231792900_B250","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1002\/1521-4141(200010)30:10%3c2972::AID-IMMU2972%3e3.0.CO;2-#","article-title":"CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease","volume":"30","author":"Cosmi","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"2021113011231792900_B251","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/ni.2104","article-title":"Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161","volume":"12","author":"Mj\u00f6sberg","year":"2011","journal-title":"Nat. Immunol."},{"key":"2021113011231792900_B252","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.bbrc.2004.02.151","article-title":"Effects of prostaglandin D2 on helper T cell functions","volume":"316","author":"Tanaka","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113011231792900_B253","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.jaci.2013.10.056","article-title":"Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells","volume":"133","author":"Xue","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B254","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0092-2019","article-title":"CD8(+) Tc2 cells: underappreciated contributors to severe asthma","volume":"28","author":"Hinks","year":"2019","journal-title":"Eur. Respir Rev."},{"key":"2021113011231792900_B255","doi-asserted-by":"publisher","first-page":"2202.e2205","DOI":"10.1016\/j.jaci.2018.10.069","article-title":"Cytokine-induced endogenous production of prostaglandin D2 is essential for human group 2 innate lymphoid cell activation","volume":"143","author":"Maric","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B256","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.4049\/jimmunol.2001245","article-title":"The roles of type 2 cytotoxic T cells in inflammation, tissue remodeling, and prostaglandin (PG) D2 production are attenuated by PGD2 receptor 2 antagonism","volume":"206","author":"Chen","year":"2021","journal-title":"J. Immunol."},{"key":"2021113011231792900_B257","doi-asserted-by":"publisher","first-page":"7580","DOI":"10.4049\/jimmunol.0804090","article-title":"Novel function of CRTH2 in preventing apoptosis of human Th2 cells through activation of the phosphatidylinositol 3-kinase pathway","volume":"182","author":"Xue","year":"2009","journal-title":"J. Immunol."},{"key":"2021113011231792900_B258","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1124\/jpet.103.055442","article-title":"Chemoattractant receptor-homologous molecule expressed on Th2 cells activation in vivo increases blood leukocyte counts and its blockade abrogates 13,14-dihydro-15-keto-prostaglandin D2-induced eosinophilia in rats","volume":"307","author":"Shichijo","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021113011231792900_B259","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4049\/jimmunol.168.1.443","article-title":"Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice","volume":"168","author":"Fujitani","year":"2002","journal-title":"J. Immunol."},{"key":"2021113011231792900_B260","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejphar.2010.04.031","article-title":"Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation","volume":"638","author":"Stebbins","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"2021113011231792900_B261","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/mi.2015.21","article-title":"The prostaglandin D(2) receptor CRTH2 regulates accumulation of group 2 innate lymphoid cells in the inflamed lung","volume":"8","author":"Tait Wojno","year":"2015","journal-title":"Mucosal Immunol."},{"key":"2021113011231792900_B262","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.4049\/jimmunol.175.4.2056","article-title":"Cutting edge: chemoattractant receptor-homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and eosinophil recruitment","volume":"175","author":"Chevalier","year":"2005","journal-title":"J. Immunol."},{"key":"2021113011231792900_B263","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0378-1119(98)00599-X","article-title":"Molecular cloning, chromosome mapping and characterization of the mouse CRTH2 gene, a putative member of the leukocyte chemoattractant receptor family","volume":"227","author":"Abe","year":"1999","journal-title":"Gene"},{"key":"2021113011231792900_B264","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.jaci.2013.01.035","article-title":"Prostaglandin D(2) pathway upregulation: relation to asthma severity, control, and TH2 inflammation","volume":"131","author":"Fajt","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B265","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/all.14001","article-title":"The impact of the prostaglandin D2 receptor 2 and its downstream effects on the pathophysiology of asthma","volume":"75","author":"Brightling","year":"2020","journal-title":"Allergy"},{"key":"2021113011231792900_B266","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/13543784.2019.1555237","article-title":"Prostaglandin D2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives","volume":"28","author":"Marone","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2021113011231792900_B267","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12931-018-0912-y","article-title":"Efficacy and safety of antagonists for chemoattractant receptor-homologous molecule expressed on Th2 cells in adult patients with asthma: a meta-analysis and systematic review","volume":"19","author":"Yang","year":"2018","journal-title":"Respir. Res."},{"key":"2021113011231792900_B268","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S2213-2600(16)30179-5","article-title":"Fevipiprant, a prostaglandin D 2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial","volume":"4","author":"Gonem","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"2021113011231792900_B269","doi-asserted-by":"publisher","first-page":"1700670","DOI":"10.1183\/13993003.00670-2017","article-title":"Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids","volume":"50","author":"Bateman","year":"2017","journal-title":"Eur. Respir. J."},{"key":"2021113011231792900_B270","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2213-2600(20)30412-4","article-title":"Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials","volume":"9","author":"Brightling","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"2021113011231792900_B271","article-title":"Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4\/5 asthma","author":"Novartis","year":"2019","journal-title":"Media Release"},{"key":"2021113011231792900_B272","doi-asserted-by":"publisher","first-page":"102030","DOI":"10.1016\/j.pupt.2021.102030","article-title":"The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant","volume":"68","author":"Brightling","year":"2021","journal-title":"Pulm. Pharmacol. Ther."},{"key":"2021113011231792900_B273","doi-asserted-by":"publisher","first-page":"100847","DOI":"10.1016\/j.eclinm.2021.100847","article-title":"Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2)","volume":"35","author":"Castro","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2021113011231792900_B274","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/cea.13524","article-title":"A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma","volume":"50","author":"Ortega","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"2021113011231792900_B275","doi-asserted-by":"publisher","first-page":"1275.e1271","DOI":"10.1016\/j.jaip.2019.11.016","article-title":"A phase 2a study of DP2 antagonist GB001 for asthma","volume":"8","author":"Asano","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2021113011231792900_B276","article-title":"GB001 phase 2 clinical trial topline results","author":"GossamerBio","year":"2020","journal-title":"News Item"},{"key":"2021113011231792900_B277","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1388-1981(99)00164-X","article-title":"The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs","volume":"1483","author":"Abramovitz","year":"2000","journal-title":"Biochim. Biophys. Acta."},{"key":"2021113011231792900_B278","first-page":"421","article-title":"Effects of inhaled prostaglandins E1, E2, and F2alpha on the airway resistance of healthy and asthmatic man","volume":"48","author":"Smith","year":"1975","journal-title":"Clin. Sci. Mol. Med."},{"key":"2021113011231792900_B279","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.pupt.2018.01.008","article-title":"Selectively targeting prostanoid E (EP) receptor-mediated cell signalling pathways: Implications for lung health and disease","volume":"49","author":"Lebender","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"2021113011231792900_B280","doi-asserted-by":"publisher","first-page":"26767","DOI":"10.1016\/S0021-9258(19)74379-8","article-title":"Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype","volume":"268","author":"Funk","year":"1993","journal-title":"J. Biol. Chem."},{"key":"2021113011231792900_B281","doi-asserted-by":"publisher","first-page":"L599","DOI":"10.1152\/ajplung.00324.2002","article-title":"Receptors and pathways mediating the effects of prostaglandin E2 on airway tone","volume":"284","author":"Tilley","year":"2003","journal-title":"Am. J Physiol. Lung Cell Mol. Physiol."},{"key":"2021113011231792900_B282","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1172\/JCI25840","article-title":"Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex","volume":"116","author":"McGraw","year":"2006","journal-title":"J. Clin. Invest."},{"key":"2021113011231792900_B283","first-page":"213","article-title":"Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype","volume":"46","author":"Regan","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"2021113011231792900_B284","doi-asserted-by":"publisher","first-page":"11873","DOI":"10.1016\/S0021-9258(17)32654-6","article-title":"Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype","volume":"269","author":"Bastien","year":"1994","journal-title":"J. Biol. Chem."},{"key":"2021113011231792900_B285","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41589-018-0131-3","article-title":"Ligand binding to human prostaglandin E receptor EP4 at the lipid-bilayer interface","volume":"15","author":"Toyoda","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"2021113011231792900_B286","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1164\/ajrccm\/148.1.87","article-title":"Effect of inhaled prostaglandin E2 on allergen-induced asthma","volume":"148","author":"Pavord","year":"1993","journal-title":"Am. Rev. Respir. Dis."},{"key":"2021113011231792900_B287","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1164\/ajrccm.159.1.9804030","article-title":"Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation","volume":"159","author":"Gauvreau","year":"1999","journal-title":"Am. J. Respir. Crit Care Med."},{"key":"2021113011231792900_B288","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1164\/ajrccm.153.2.8564099","article-title":"Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma","volume":"153","author":"Szczeklik","year":"1996","journal-title":"Am. J. Respir. Crit Care Med."},{"key":"2021113011231792900_B289","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1164\/ajrccm.161.supplement_1.ltta-14","article-title":"Leukotriene bronchoconstriction induced by allergen and exercise","volume":"161","author":"O\u2019Byrne","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021113011231792900_B290","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1136\/thx.2010.158568","article-title":"EP4 receptor as a new target for bronchodilator therapy","volume":"66","author":"Buckley","year":"2011","journal-title":"Thorax"},{"key":"2021113011231792900_B291","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1165\/rcmb.2012-0158OC","article-title":"Differential regulation of airway smooth muscle cell migration by E-prostanoid receptor subtypes","volume":"48","author":"Aso","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2021113011231792900_B292","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.4049\/jimmunol.169.7.3963","article-title":"The immunomodulatory actions of prostaglandin E2 on allergic airway responses in the rat","volume":"169","author":"Martin","year":"2002","journal-title":"J. Immunol."},{"key":"2021113011231792900_B293","doi-asserted-by":"publisher","first-page":"L105","DOI":"10.1152\/ajplung.00221.2005","article-title":"Prostaglandin E2 protects lower airways against bronchoconstriction","volume":"290","author":"Hartney","year":"2006","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2021113011231792900_B294","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/thoraxjnl-2014-206592","article-title":"Anti-inflammatory effects of PGE2 in the lung: role of the EP4 receptor subtype","volume":"70","author":"Birrell","year":"2015","journal-title":"Thorax"},{"key":"2021113011231792900_B295","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1182\/blood-2005-07-2772","article-title":"Human mast cells express multiple EP receptors for prostaglandin E2 that differentially modulate activation responses","volume":"107","author":"Feng","year":"2006","journal-title":"Blood"},{"key":"2021113011231792900_B296","doi-asserted-by":"publisher","first-page":"1232.e1231","DOI":"10.1016\/j.jaci.2015.04.002","article-title":"Prostaglandin E2 inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor","volume":"136","author":"S\u00e4fholm","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B297","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaci.2019.04.031","article-title":"Mannitol triggers mast cell-dependent contractions of human small bronchi and prostacyclin bronchoprotection","volume":"144","author":"S\u00e4fholm","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B298","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/cea.12542","article-title":"Activation of the Prostaglandin E2 receptor EP2 prevents house dust mite-induced airway hyperresponsiveness and inflammation by restraining mast cells' activity","volume":"45","author":"Serra-Pages","year":"2015","journal-title":"Clin. Exp. Allergy"},{"key":"2021113011231792900_B299","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.phrs.2012.12.008","article-title":"Locally administered prostaglandin E2 prevents aeroallergen-induced airway sensitization in mice through immunomodulatory mechanisms","volume":"70","author":"Torres","year":"2013","journal-title":"Pharmacol. Res."},{"key":"2021113011231792900_B300","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaci.2013.07.037","article-title":"Prostaglandin E(2) suppresses allergic sensitization and lung inflammation by targeting the E prostanoid 2 receptor on T cells","volume":"133","author":"Zas\u0142ona","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B301","doi-asserted-by":"publisher","first-page":"1761.e1766","DOI":"10.1016\/j.jaci.2017.09.050","article-title":"Prostaglandin E2 suppresses human group 2 innate lymphoid cell function","volume":"141","author":"Maric","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021113011231792900_B302","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fimmu.2018.00501","article-title":"Prostaglandin E2 inhibits group 2 innate lymphoid cell activation and allergic airway inflammation through E-prostanoid 4-cyclic adenosine monophosphate signaling","volume":"9","author":"Zhou","year":"2018","journal-title":"Front. Immunol."},{"key":"2021113011231792900_B303","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.pupt.2017.11.001","article-title":"Activating prostaglandin E2 receptor subtype EP4 increases secreted mucin from airway goblet cells","volume":"48","author":"Akaba","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"2021113011231792900_B304","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3389\/fmed.2017.00104","article-title":"Prostaglandins and their receptors in eosinophil function and as therapeutic targets","volume":"4","author":"Peinhaupt","year":"2017","journal-title":"Front. Med. (Lausanne)"},{"key":"2021113011231792900_B305","doi-asserted-by":"publisher","first-page":"10978","DOI":"10.1073\/pnas.93.20.10978","article-title":"Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells","volume":"93","author":"Fedyk","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011231792900_B306","doi-asserted-by":"publisher","first-page":"20505","DOI":"10.1038\/srep20505","article-title":"Prostaglandins E2 signal mediated by receptor subtype EP2 promotes IgE production in vivo and contributes to asthma development","volume":"6","author":"Gao","year":"2016","journal-title":"Sci. Rep."},{"key":"2021113011231792900_B307","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3389\/fimmu.2020.01224","article-title":"PPARgamma as an E3 ubiquitin-ligase impedes phosphate-Stat6 stability and promotes prostaglandins E2-mediated inhibition of IgE production in asthma","volume":"11","author":"Wu","year":"2020","journal-title":"Front. Immunol."},{"key":"2021113011231792900_B308","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1042\/bj2980263","article-title":"Cloning and expression of a prostaglandin E receptor EP3 subtype from human erythroleukaemia cells","volume":"298","author":"Kunapuli","year":"1994","journal-title":"Biochem. J."},{"key":"2021113011231792900_B309","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.pharmthera.2004.06.003","article-title":"Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation","volume":"103","author":"Hata","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"2021113011231792900_B310","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41589-018-0171-8","article-title":"Crystal structure of the endogenous agonist-bound prostanoid receptor EP3","volume":"15","author":"Morimoto","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"2021113011231792900_B311","doi-asserted-by":"publisher","first-page":"11712","DOI":"10.1073\/pnas.0701700104","article-title":"Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 receptor 3","volume":"104","author":"Weller","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011231792900_B312","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1164\/rccm.200903-0388OC","article-title":"Prostaglandin E2 mediates cough via the EP3 receptor: implications for future disease therapy","volume":"180","author":"Maher","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021113011231792900_B313","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.coph.2011.06.005","article-title":"G-protein coupled receptors regulating cough","volume":"11","author":"Maher","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"2021113011231792900_B314","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/ni1188","article-title":"Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3","volume":"6","author":"Kunikata","year":"2005","journal-title":"Nat. Immunol."},{"key":"2021113011231792900_B315","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/01.CIR.90.4.1643","article-title":"Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system","volume":"90","author":"Nakagawa","year":"1994","journal-title":"Circulation"},{"key":"2021113011231792900_B316","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.rmed.2009.07.015","article-title":"A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension","volume":"104","author":"Mubarak","year":"2010","journal-title":"Respir. Med."},{"key":"2021113011231792900_B317","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1152\/jappl.1985.58.3.859","article-title":"Endogenous prostaglandins modulate histamine-induced contraction in canine tracheal smooth muscle","volume":"58","author":"Shore","year":"1985","journal-title":"J. Appl. Physiol."},{"key":"2021113011231792900_B318","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.08.001","article-title":"Prostaglandins in asthma and allergic diseases","volume":"193","author":"Peebles","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"2021113011231792900_B319","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1165\/rcmb.2003-0035OC","article-title":"Role of prostaglandin I2 in airway remodeling induced by repeated allergen challenge in mice","volume":"29","author":"Nagao","year":"2003","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2021113011231792900_B320","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1172\/JCI28949","article-title":"Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function","volume":"117","author":"Idzko","year":"2007","journal-title":"J. Clin. Invest."},{"key":"2021113011231792900_B321","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/j.1365-2222.2010.03558.x","article-title":"Iloprost has potent anti-inflammatory properties on human monocyte-derived dendritic cells","volume":"40","author":"M\u00fcller","year":"2010","journal-title":"Clin. Exp. Allergy"},{"key":"2021113011231792900_B322","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1189\/jlb.1112559","article-title":"PGI(2) signaling inhibits antigen uptake and increases migration of immature dendritic cells","volume":"94","author":"Toki","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"2021113011231792900_B323","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.4049\/jimmunol.179.9.6193","article-title":"Prostaglandin I-2-PP signaling blocks allergic pulmonary inflammation by preventing recruitment of CD4(+) th2 cells into the airways in a mouse model of asthma","volume":"179","author":"Jaffar","year":"2007","journal-title":"J. Immunol."},{"key":"2021113011231792900_B324","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.4049\/jimmunol.1700605","article-title":"The PGI2 analog cicaprost inhibits IL-33-induced Th2 responses, IL-2 production, and CD25 expression in mouse CD4(+) T cells","volume":"201","author":"Zhou","year":"2018","journal-title":"J. Immunol."},{"key":"2021113011231792900_B325","doi-asserted-by":"publisher","first-page":"e140690","DOI":"10.1172\/JCI140690","article-title":"Prostaglandin I2 signaling licenses Treg suppressive function and prevents pathogenic reprogramming","volume":"131","author":"Norlander","year":"2021","journal-title":"J. Clin. Invest."},{"key":"2021113011231792900_B326","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1164\/rccm.201410-1793OC","article-title":"Prostaglandin I2 signaling and inhibition of Group 2 innate lymphoid cell responses","volume":"193","author":"Zhou","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021113011231792900_B327","doi-asserted-by":"publisher","first-page":"461","DOI":"10.4049\/jimmunol.1600275","article-title":"PGI2 controls pulmonary NK cells that prevent airway sensitization to house dust mite allergen","volume":"198","author":"Simons","year":"2017","journal-title":"J. Immunol."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/135\/16\/1945\/919151\/cs-2019-0657c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/135\/16\/1945\/919151\/cs-2019-0657c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T08:43:23Z","timestamp":1673081003000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/135\/16\/1945\/229566\/Eicosanoid-receptors-as-therapeutic-targets-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":327,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021,8,27]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20190657","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8]]},"published":{"date-parts":[[2021,8]]}}}